1. Home
  2. RXST vs DCTH Comparison

RXST vs DCTH Comparison

Compare RXST & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RxSight Inc.

RXST

RxSight Inc.

N/A

Current Price

$6.36

Market Cap

305.0M

Sector

Health Care

ML Signal

N/A

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

N/A

Current Price

$8.93

Market Cap

323.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RXST
DCTH
Founded
1997
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
305.0M
323.1M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
RXST
DCTH
Price
$6.36
$8.93
Analyst Decision
Hold
Strong Buy
Analyst Count
11
4
Target Price
$11.60
$22.00
AVG Volume (30 Days)
612.2K
431.5K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.07
Revenue
$134,479,000.00
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
$9.57
$33.15
P/E Ratio
N/A
$129.57
Revenue Growth
N/A
N/A
52 Week Low
$6.35
$8.12
52 Week High
$27.13
$18.23

Technical Indicators

Market Signals
Indicator
RXST
DCTH
Relative Strength Index (RSI) 29.02 41.48
Support Level N/A $8.90
Resistance Level $9.11 $10.17
Average True Range (ATR) 0.41 0.34
MACD -0.08 -0.02
Stochastic Oscillator 16.50 4.58

Price Performance

Historical Comparison
RXST
DCTH

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: